Thanks for the excellent scenario, Dave.
A few points to add about POC troponin and STEMI / NSTEMI care:
* Troponins can take a long time to bump, so a single negative troponin is not an effective cardiac rule-out
* Conversely, most NSTEMI patients don't require emergent catheterisation
* The presence of absence of STEMI indicates the need for emergent reperfusion therapy. If there's a STEMI pattern, they need to either be lysed or cathed, depending on their risk factors, comorbidities, the availability of cathlab, and the age of their MI.
* In the first 2 hours, field fibrinolysis may actually outperform PCI (*Unless your site is basically always ready to go, and has an open suite 24-7, it is extremtly hard to actually cath someone in the first 60-90 mins of an MI -- a paramedic team can have someone lysed in 25 minutes, sometimes quicker), and has at least comparable benefit in carefully selected patients.
Re: TXA
* CRASH-2 is a great study because it shows that even in a broad, poorly differentiated population, there was no real increase in thromboembolic events. No one really infarcted or stroked out. The only patients who did badly were those with non-recent injuries.
* MATTERS is another good study to look at; this was performed by the military, so it used predominantly younger and baseline-healthier individuals, but they were also much more severely injured. It showed a much greater mortality benefit, suggesting that some of the benefit of TXA may have been masked in CRASH-2 by a subgroup of less severely injured patients who were at little risk of dying, and little risk of benefiting from the TXA, making the effect seem smaller.
* It's a very safe drug, with a pretty large benefit. More places should be using it.